Perrigo Set to Announce Q4 Earnings on February 26
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 10 hours ago
0mins
Should l Buy PRGO?
Source: seekingalpha
- Earnings Announcement: Perrigo (PRGO) is set to release its Q4 earnings on February 26 before market open, with a consensus EPS estimate of $0.78, reflecting a 16.1% year-over-year decline, indicating potential profitability challenges for the company.
- Revenue Decline: The expected revenue for Q4 is $1.09 billion, down 4.4% year-over-year, highlighting possible challenges the company faces in a competitive market, particularly amid soft consumer demand.
- Historical Performance Review: Over the past two years, Perrigo has beaten EPS estimates 75% of the time but only 38% of the time for revenue, suggesting significant volatility in the company's profitability that may affect investor confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates saw one upward revision and two downward revisions, while revenue estimates experienced no upward revisions and two downward revisions, reflecting analysts' cautious outlook on the company's future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRGO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRGO
Wall Street analysts forecast PRGO stock price to rise
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 14.610
Low
18.00
Averages
20.33
High
23.00
Current: 14.610
Low
18.00
Averages
20.33
High
23.00
About PRGO
Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Perrigo Set to Announce Q4 Earnings on February 26
- Earnings Announcement: Perrigo (PRGO) is set to release its Q4 earnings on February 26 before market open, with a consensus EPS estimate of $0.78, reflecting a 16.1% year-over-year decline, indicating potential profitability challenges for the company.
- Revenue Decline: The expected revenue for Q4 is $1.09 billion, down 4.4% year-over-year, highlighting possible challenges the company faces in a competitive market, particularly amid soft consumer demand.
- Historical Performance Review: Over the past two years, Perrigo has beaten EPS estimates 75% of the time but only 38% of the time for revenue, suggesting significant volatility in the company's profitability that may affect investor confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates saw one upward revision and two downward revisions, while revenue estimates experienced no upward revisions and two downward revisions, reflecting analysts' cautious outlook on the company's future performance.
See More
High Yield Comeback: 3 Cash-Heavy Dividend Stocks at Discount
Investor Trends: Investors are shifting focus from high-growth technology stocks to dividend-paying stocks, seeking reliable income amidst market volatility and low interest rates.
Dividend Strategy: Companies that offer high-yield dividends are attractive to investors due to their steady cash flows, providing a defense against market fluctuations and generating income.
Healthcare REITs: Omega Healthcare Investors, a real estate investment trust (REIT), is gaining attention for its focus on skilled nursing facilities, which are expected to see increased demand due to an aging population.
Market Recommendations: Analysts are suggesting five specific stocks for investors to consider now, emphasizing their potential for high yields and value amidst broader market conditions.
See More
Perrigo Announces Quarterly Dividend of $0.29 per Share
- Quarterly Dividend Announcement: Perrigo's Board of Directors has approved a quarterly dividend of $0.29 per share, translating to an annualized rate of $1.16 per share, reflecting the company's robust cash flow and profitability, which bolsters investor confidence.
- Payment Date Set: The cash dividend is scheduled for payment on March 24, 2026, to shareholders of record as of March 2, 2026, ensuring timely returns for shareholders and strengthening the company's relationship with its investors.
- Market Positioning: As a leading consumer health company with over a century of experience, Perrigo focuses on over-the-counter self-care products in North America and Europe, addressing consumer demand for health and wellness solutions, thereby enhancing its competitive edge in the market.
- Brand Strategy: Perrigo's unique business model leverages strong private label offerings to fuel investments in well-known brands like Opill® and Mederma®, which not only enhances brand value but also promotes growth potential in the rapidly evolving self-care market.
See More
Perrigo Declares Quarterly Dividend of $0.29
- Dividend Declaration: Perrigo has declared a quarterly dividend of $0.29 per share, consistent with previous distributions, indicating the company's stable cash flow and profitability, which enhances investor confidence.
- Yield Analysis: The forward yield of 7.96% makes this dividend attractive in the current market environment, potentially drawing in income-seeking investors and increasing the stock's appeal.
- Payment Schedule: The dividend is payable on March 24, with a record date of March 2 and an ex-dividend date also on March 2, ensuring shareholders receive their earnings promptly, which may enhance shareholder loyalty.
- Dividend Growth Trend: Perrigo's dividend growth trend reflects its ongoing financial health, suggesting that the company may continue to maintain or increase dividend payments in the future, thereby attracting long-term investors.
See More
FDA Pushes for Prescription Drugs to Become Over-the-Counter
- Policy Advocacy: FDA Commissioner Marty Makary stated in Washington that the agency plans to push for more prescription drugs to become over-the-counter (OTC) this year, aiming to improve drug accessibility and reduce healthcare costs, which could allow patients to obtain basic safe medications without a doctor's visit.
- Regulatory Streamlining: Legislation passed by Congress in November simplifies the regulatory process for transitioning prescription drugs to OTC status, including full, conditional, and partial switch pathways, which is expected to accelerate drug availability and enhance patient convenience in medication access.
- Increased Transparency: Makary emphasized that OTC sales would bypass insurers and pharmacy benefit managers, potentially lowering drug prices and increasing transparency, with cash prices for OTC medications possibly being lower than patients' copays for prescription drugs, thereby alleviating financial burdens on patients.
- Industry Pushback: The pharmaceutical industry has raised concerns about this policy, arguing that OTC drugs may not be covered by insurance, leading to higher costs for patients, and that the FDA lacks authority over drug pricing, necessitating thorough consultations with manufacturers before any transitions.
See More
Perrigo to Release Q4 and FY 2025 Financial Results
- Earnings Release Schedule: Perrigo Company plans to issue its Q4 and FY 2025 financial results on February 26, 2026, indicating the company's commitment to transparency and investor communication.
- Conference Call Details: Following the earnings release, Perrigo will host a conference call at 8:30 A.M. EST, providing a live webcast to ensure investors receive timely key information, thereby enhancing market confidence.
- Replay Service: A taped replay of the call will be available starting at 12:00 P.M. EST on February 26 until midnight on March 5, allowing investors who cannot participate live to access the information, further improving information accessibility.
- Company Background: Perrigo is a leading consumer health company focused on the OTC self-care market, leveraging its strong brand portfolio and unique business model to drive growth and meet consumer needs.
See More
Perrigo Set to Announce Q4 Earnings on February 26
- Earnings Announcement: Perrigo (PRGO) is set to release its Q4 earnings on February 26 before market open, with a consensus EPS estimate of $0.78, reflecting a 16.1% year-over-year decline, indicating potential profitability challenges for the company.
- Revenue Decline: The expected revenue for Q4 is $1.09 billion, down 4.4% year-over-year, highlighting possible challenges the company faces in a competitive market, particularly amid soft consumer demand.
- Historical Performance Review: Over the past two years, Perrigo has beaten EPS estimates 75% of the time but only 38% of the time for revenue, suggesting significant volatility in the company's profitability that may affect investor confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates saw one upward revision and two downward revisions, while revenue estimates experienced no upward revisions and two downward revisions, reflecting analysts' cautious outlook on the company's future performance.
See More
High Yield Comeback: 3 Cash-Heavy Dividend Stocks at Discount
Investor Trends: Investors are shifting focus from high-growth technology stocks to dividend-paying stocks, seeking reliable income amidst market volatility and low interest rates.
Dividend Strategy: Companies that offer high-yield dividends are attractive to investors due to their steady cash flows, providing a defense against market fluctuations and generating income.
Healthcare REITs: Omega Healthcare Investors, a real estate investment trust (REIT), is gaining attention for its focus on skilled nursing facilities, which are expected to see increased demand due to an aging population.
Market Recommendations: Analysts are suggesting five specific stocks for investors to consider now, emphasizing their potential for high yields and value amidst broader market conditions.
See More
Perrigo Announces Quarterly Dividend of $0.29 per Share
- Quarterly Dividend Announcement: Perrigo's Board of Directors has approved a quarterly dividend of $0.29 per share, translating to an annualized rate of $1.16 per share, reflecting the company's robust cash flow and profitability, which bolsters investor confidence.
- Payment Date Set: The cash dividend is scheduled for payment on March 24, 2026, to shareholders of record as of March 2, 2026, ensuring timely returns for shareholders and strengthening the company's relationship with its investors.
- Market Positioning: As a leading consumer health company with over a century of experience, Perrigo focuses on over-the-counter self-care products in North America and Europe, addressing consumer demand for health and wellness solutions, thereby enhancing its competitive edge in the market.
- Brand Strategy: Perrigo's unique business model leverages strong private label offerings to fuel investments in well-known brands like Opill® and Mederma®, which not only enhances brand value but also promotes growth potential in the rapidly evolving self-care market.
See More
Perrigo Declares Quarterly Dividend of $0.29
- Dividend Declaration: Perrigo has declared a quarterly dividend of $0.29 per share, consistent with previous distributions, indicating the company's stable cash flow and profitability, which enhances investor confidence.
- Yield Analysis: The forward yield of 7.96% makes this dividend attractive in the current market environment, potentially drawing in income-seeking investors and increasing the stock's appeal.
- Payment Schedule: The dividend is payable on March 24, with a record date of March 2 and an ex-dividend date also on March 2, ensuring shareholders receive their earnings promptly, which may enhance shareholder loyalty.
- Dividend Growth Trend: Perrigo's dividend growth trend reflects its ongoing financial health, suggesting that the company may continue to maintain or increase dividend payments in the future, thereby attracting long-term investors.
See More
FDA Pushes for Prescription Drugs to Become Over-the-Counter
- Policy Advocacy: FDA Commissioner Marty Makary stated in Washington that the agency plans to push for more prescription drugs to become over-the-counter (OTC) this year, aiming to improve drug accessibility and reduce healthcare costs, which could allow patients to obtain basic safe medications without a doctor's visit.
- Regulatory Streamlining: Legislation passed by Congress in November simplifies the regulatory process for transitioning prescription drugs to OTC status, including full, conditional, and partial switch pathways, which is expected to accelerate drug availability and enhance patient convenience in medication access.
- Increased Transparency: Makary emphasized that OTC sales would bypass insurers and pharmacy benefit managers, potentially lowering drug prices and increasing transparency, with cash prices for OTC medications possibly being lower than patients' copays for prescription drugs, thereby alleviating financial burdens on patients.
- Industry Pushback: The pharmaceutical industry has raised concerns about this policy, arguing that OTC drugs may not be covered by insurance, leading to higher costs for patients, and that the FDA lacks authority over drug pricing, necessitating thorough consultations with manufacturers before any transitions.
See More
Perrigo to Release Q4 and FY 2025 Financial Results
- Earnings Release Schedule: Perrigo Company plans to issue its Q4 and FY 2025 financial results on February 26, 2026, indicating the company's commitment to transparency and investor communication.
- Conference Call Details: Following the earnings release, Perrigo will host a conference call at 8:30 A.M. EST, providing a live webcast to ensure investors receive timely key information, thereby enhancing market confidence.
- Replay Service: A taped replay of the call will be available starting at 12:00 P.M. EST on February 26 until midnight on March 5, allowing investors who cannot participate live to access the information, further improving information accessibility.
- Company Background: Perrigo is a leading consumer health company focused on the OTC self-care market, leveraging its strong brand portfolio and unique business model to drive growth and meet consumer needs.
See More
